The ability of antibodies to bind their target proteins with some degree of specificity has elevated them to being among the most useful tools in biology and medicine, with a market value of $60 billion.
Molecular profiling is becoming increasingly important as a tool for the discovery and implementation of novel biomarkers for use in drug development. Modern profiling methods permit comprehensive analysis of biological systems that allow, for the first time, non-hypothesis-driven approaches in biological discovery.
The genomics community has made great strides in our understanding of the molecular basis of cancer and these advances are slowly beginning to change the way we diagnose and treat patients. But genomic studies alone cannot capture the complete view of disease processes - a more comprehensive approach is needed.